COLL Q1 2024 Earnings — Collegium Pharmaceutical, Inc. Revenue & Financial Results | Market Cap Arena

COLLCollegium Pharmaceutical, Inc.

$1B

Q1 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$145M+0.1% YoY

Gross Profit

$91M63.1% margin

Operating Income

$49M34.1% margin

Net Income

$28M19.1% margin

EPS (Diluted)

$0.71

QoQ Revenue Growth

-3.2%

Cash Flow

Operating Cash Flow

$62M

Free Cash Flow

$61M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$892M

Stockholders' Equity

$222M

Cash & Equivalents

$229M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$145M	$145M	+0.1%
Gross Profit	$91M	$77M	+18.2%
Operating Income	$49M	$25M	+100.9%
Net Income	$28M	-$17M	+259.0%

Revenue Segments

Belbuca

$51M35%

Xtampza ER

$46M32%

Nucynta IR

$26M18%

Nucynta ER

$19M13%

Symproic

$3M2%